Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEUS phase 3 trial of SAR442168 in primary progressive multiple sclerosis
MOH_2021-01-19_009684Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing SAR442168 with Placebo (2 arms). Primary endpoint: Time to 6-month confirmed disability progression. Started Dec 2020; status: active, not recruiting.
02
Drugs
tolebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on MOH_2021-01-19_009684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-19_009684.